Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010
Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010
Othello Syndrome in Parkinson Disease Patients Without Dementia
The Neurologist 15:34-36, Cannas,A.,et al, 2009
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008
Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease
Arch Neurol 65:1604-1611, Cilia,R.,et al, 2008
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007
Randomized, Blind, Controlled Trial of Transdermal Rotigotine in Early Parkinson Disease
Neurol 68:272-276, Watts,R.L.,et al, 2007
Pathologic Gambling in Patients with Restless Legs Syndrome Treated With Dopaminergic Agonists
Neurol 68:301-303, Tippmann-Peikert,M.,et al, 2007
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007
Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole
Arch Neurol 64:820-824, Kleiner-Fisman,G. &Fisman,D.N., 2007
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Hiccups Associated with Dopamine Agonists in Parkinson Disease
Neurol 66:774-775, Sharma,P.,et al, 2006
Prospective Prevalence of Pathologic Gambling and Medication Association in Parkinson Disease
Neurol 66:1750-1752, Voon,V.,et al, 2006
Efficacy and Safety of Pramipexole in Restless Legs Syndrome
Neurol 67:1034-1039, Winkelman,J.W.,et al, 2006
Efficacy of Cabergoline in Restless Legs Syndrome, A Placebo-Controlled Study with Polysomnography (CATOR)
Neurol 67:1040-1046, Oertel,W.H.,et al, 2006
Dopamine Agonists and Cardiac Valvulopathy in Parkinson Disease: A Case-Control Study
Neurol 67:1225-1229, Yamamoto,M.,et al, 2006
Psychosis Related to Ropinirole
Am J Psychiatry 163:546-547, Perea,E.,et al, 2006
Pleuropulmonary Fibrosis After Long-term Treatment With the Dopamine Agonist Pergolide for Parkinson Disease
Arch Neurol 62:1290-1295, Tintner,R.,et al, 2005
Sudden Uncontrollable Somnolence and Medication Use in Parkinson Disease
Arch Neurol 62:1242-1248, Avorn,J.,et al, 2005
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Arch Neurol 62:1377-1381, Dodd,M.L.,et al, 2005
Cabergoline-Related Severe Restrictive Mitral Regurgitation
NEJM 353:1974-1975, Rosen,C.J., 2005
Treatment of Parkinson's Disease with Pergolide and Relation to Restrictive Valvular Heart Disease
Lancet 363:1179-1183, Van Camp,G.,et al, 2004
Restless Legs Syndrome
NEJM 348:2103-2109, Earley,C.J., 2003
Pathological Gambling Associated with Dopamine Agonist Therapy in Parkinson's
Neurol 61:422-423, Driver-Dunckley,E.,et al, 2003
Heart Valvular Disease in Patients with Parkinson's Disease Treated with High-Dose Pergolide
Neurol 61:859-861, VanCamp,G.,et al, 2003
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
NEJM 349:2023-2033, Colao,A.,et al, 2003
Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease
JAMA 287:455-463,509, Hobson,D.E.,et al, 2002
Alopecia Induced by Dopamine Agonists
Neurol 58:829-830, Tabamo,R.E. &Di Rocco,A., 2002
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
Dopamine Agonists: Their Role in the Treatment of Parkinson's Disease
JNNP 68;685-690, Brooks,D.J., 2000
Clinical Characteristics of Pramipexole-Induced Peripheral Edema
Arch Neurol 57:729-732, Tan,E.K.&Ondo,W., 2000
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
Acute Orhtostatic Hypotension When Starting Dopamine Agonists in Parkinson's Disease
Arch Neurol 57:1461-1463, Kujawa,K.,et al, 2000
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease
JAMA 284:1931-1938,1971, Parkinson Study Group, 2000
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Falling Asleep at the Wheel:Motor Vehicle Mishaps in Persons Taking Pramipexole and Ropinirole
Neurol 52:1908-1910, Frucht,S.,et al, 1999
Safety and Efficacy of Pramipexole in Early Parkinson Disease
Parkinson Study Group, JAMA 278:125-1301997., , 1997
Clinical Evaluation of Pramipexole in Advanced Parkinson's Disease
Neurol 49:162-168, Lieberman,A.,et al, 1997
Efficacy of Pramipexole, A Novel Dopamine Agonist, As Monotherapy in Mild to Moderate Parkinson's Disease
Neurol 49:724-728, Shannon,K.M.,et al, 1997
Double-Blind Comparison of Pramipexole & Bromocriptine Trtm with Placebo in Advanced Parkinson's Disease
Neurol 49:1060-1065, Guttman,M.,et al, 1997
Chiasmal Herniation as a Complication of Bromocriptine Therapy
J Neuro-Ophthalmol 16:252-257, Taxel,P.,et al, 1996
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Retroperitoneal Fibrosis in a Patient with Parkinson's Disease Treated with Pergolide
Clin NeuroPharmacol 18:277-279, Jimenez-Jimenez,F.J.,et al, 1995
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994